There are 2789 resources available
LBA40 - SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
Presenter: Paolo Ascierto
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1041MO - 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
Presenter: Reinhard Dummer
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA67 - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy
Presenter: Jaume Capdevila
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1743MO - MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation
Presenter: Sophie Leboulleux
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1099MO - Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
Presenter: Jorge Hernando
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1100MO - Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Presenter: Halfdan Sorbye
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1101MO - Development of CAR T-cells for future treatment of NETs
Presenter: Barbara Mandriani
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
519MO - Concordance analysis of treatment recommendations between central consensus and multidisciplinary tumor boards
Presenter: Hidenori Kage
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
520MO - Using patient-reported outcomes (PROs) in dose-finding oncology trials (DFOT): Results from a global stakeholder survey and the National Cancer Research Institute (NCRI) Consumer Forum
Presenter: Julia Lai-Kwon
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
343MO - Clinical features and DNA methylation patterns in long- and short-term survivors of WHO grade II-III glioma
Presenter: Maximilian Mair
Session: Mini oral session - CNS tumours
Resources:
Abstract
Slides
Webcast